Incidence and Treatment Outcomes of Pharyngeal. Infections in Men Who Have Sex with Men: A 13-Year Retrospective Cohort Study
|
|
- Beverly Horn
- 5 years ago
- Views:
Transcription
1 MAJOR ARTICLE Incidence and Treatment Outcomes of Pharyngeal Neisseria gonorrhoeae and Chlamydia trachomatis Infections in Men Who Have Sex with Men: A 13-Year Retrospective Cohort Study Kaede V. Ota, 1,2 David N. Fisman, 1,2,3 Itamar E. Tamari, 4 Marek Smieja, 5,6 Lai-King Ng, 7 Karen E. Jones, 2 Alessandro DiPrima, 3 and Susan E. Richardson 1,2,3 1 The Hospital for Sick Children, 2 University of Toronto, 3 Public Health Laboratory, Ontario Agency for Health Protection and Promotion (formerly Ontario Ministry of Health and Long-Term Care), and 4 Hassle Free Men s Clinic, Toronto, Ontario, Canada; 5 Departments of Pathology and Molecular Medicine and 6 Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada; and 7 Public Health Agency of Canada, National Microbiology Laboratory, Winnipeg, Manitoba, Canada Background. This study investigated the incidence and treatment outcomes of pharyngeal Neisseria gonorrhoeae and Chlamydia trachomatis cases at a Canadian clinic that mainly serves men who have sex with men. Methods. All patients with pharyngeal N. gonorrhoeae and C. trachomatis infections detected from 1 January 1995 through 31 December 2007 were identified. Original and test-of-cure N. gonorrhoeae culture isolates were compared using antibiotic susceptibility testing and N. gonorrhoeae multiantigen sequence typing. Results. One hundred seventy-eight cases of pharyngeal N. gonorrhoeae infection and 97 cases of pharyngeal C. trachomatis infection were identified, primarily by culture methods. The mean incidence was 1.62 and 0.81 cases per 1000 visits per year for N. gonorrhoeae and C. trachomatis infection, respectively. Poisson regression modeling demonstrated a statistically significant surge of pharyngeal N. gonorrhoeae cases in 2007 after controlling for seasonal and long-term oscillation and long-term linear trends. Among patients with pharyngeal N. gonorrhoeae and C. trachomatis infection, 60.2% and 84.3%, respectively, would have been missed by relying on urine and urethral testing. Nine percent of patients with pharyngeal N. gonorrhoeae and 4.3% of patients with pharyngeal C. trachomatis infection who underwent test-of-cure procedures had at least 1 positive result. Antibiograms were not different in 8 of 10 pretreatment and posttreatment N. gonorrhoeae isolate pairs. N. gonorrhoeae multiantigen sequence typing results were identical in 2 of these cases. Public health records documented abstinence in both individuals. Conclusions. Nine percent of cases with pharyngeal N. gonorrhoeae and 4.3% of cases with pharyngeal C. trachomatis infection that underwent tests of cure had positive results. Available typing results suggest antibiotic treatment failure rather than reinfection. Specific antibiotic treatment regimens for pharyngeal N. gonorrhoeae and C. trachomatis infections need to be developed and formally evaluated. Neisseria gonorrhoeae and Chlamydia trachomatis infections are a significant problem among men who have sex with men, because of high rates of unprotected sex [1]. The pharynx is a frequently overlooked reservoir for these pathogens. Pharyngeal N. gonorrhoeae and C. Received 5 October 2008; accepted 5 January 2009; electronically published 26 March Reprints or correspondence: Dr. Susan E. Richardson, Division of Microbiology, Pediatric Laboratory Medicine, The Hospital for Sick Children, 555 University Ave., Toronto, Ontario, Canada M5G 1X8 (susan.richardson@sickkids.ca). Clinical Infectious Diseases 2009; 48: by the Infectious Diseases Society of America. All rights reserved /2009/ $15.00 DOI: / trachomatis infections are well documented in the literature, with a recent study reporting a prevalence of 9.2% for pharyngeal N. gonorrhoeae and 1.4% for pharyngeal C. trachomatis in a population of men who have sex with men [2]. Moreover, data in the literature have reported urethral N. gonorrhoeae infections associated with insertive oral sex [3] and pharyngeal N. gonorrhoeae associated with receptive oral sex [4], providing evidence that not only does N. gonorrhoeae colonize the pharynx, it also appears to be transmitted bidirectionally through oral-penile contact [4]. Effective antimicrobial therapy is required for the eradication of N. gonorrhoeae and C. trachomatis from Pharyngeal Gonorrhea and Chlamydia CID 2009:48 (1 May) 1237
2 the pharynx; however, data documenting the efficacy of commonly used antimicrobial regimens are lacking. This retrospective cohort study documented the incidence of pharyngeal N. gonorrhoeae and C. trachomatis infections at a Canadian clinic for men who have sex with men and investigated treatment outcomes. METHODS Data collection. Clinic records from the Hassle Free Men s Clinic in Toronto, Ontario, Canada, were used to identify all patients with pharyngeal N. gonorrhoeae and C. trachomatis infections detected from 1 January 1995 through 31 December This clinic serves a large population of men who have sex with men from Toronto and the surrounding area. Clinic medical records were used to extract the following data: the antibiotic regimen administered, test-of-cure results, and the presence of N. gonorrhoeae and/or C. trachomatis at other anatomical sites. Antibiotic susceptibility testing results were recorded for patients with pharyngeal N. gonorrhoeae infection. For individuals who did not receive antibiotic therapy, public health documentation of attempts to contact the individual were noted. The clinic policy during the study period was to sample the pharynx, rectum, and urethra (or urine) for N. gonorrhoeae and C. trachomatis in patients presenting for sexually transmitted disease screening, regardless of the presence or absence of symptoms. It was also their policy to perform 2 tests of cure by culture in all cases of culture-positive pharyngeal N. gonorrhoeae and C. trachomatis infection at 2 and 3 weeks after completion of antibiotic therapy. N. gonorrhoeae and C. trachomatis cultures were performed at the Public Health Laboratory, Ontario Agency for Health Protection and Promotion (formerly, the Ontario Ministry of Health and Long-Term Care), in Toronto. Urine specimens were tested for N. gonorrhoeae and C. trachomatis with use of the BD ProbeTec ET system (ProbeTec; Becton Dickinson). Urethral specimens were obtained for N. gonorrhoeae culture in individuals who presented with urethral symptoms. These policies and practices were consistent throughout the period studied. This study was approved by the research ethics board at the Hospital for Sick Children in Toronto, Canada. Cohort of patients with pharyngeal N. gonorrhoeae and C. trachomatis detected by molecular methods. In 2007, additional patients were recruited from a study that evaluated the performance of the ProbeTec and APTIMA Combo 2 assays (APTIMA; Gen-Probe) in detecting pharyngeal and rectal N. gonorrhoeae and C. trachomatis infections; this study was also conducted at the Hassle Free Men s Clinic [5]. Pharyngeal and rectal specimens were obtained for N. gonorrhoeae and C. trachomatis testing by culture, ProbeTec, and APTIMA assays. Positive results of the APTIMA test were confirmed using the ACT and AGC assays (Gen-Probe). Tests of cure were performed using culture, ProbeTec, and APTIMA tests at 3 and 4 weeks after the completion of treatment. For the purpose of analysis, a positive pharyngeal nucleic acid amplification test result was deemed a true-positive result if (1) a second assay result was positive or (2) the patient had a positive result for the same organism at another anatomical site [5]. Details pertaining to this study have been published elsewhere [5]. In this cohort of patients, 28 individuals had positive results for pharyngeal N. gonorrhoeae by ProbeTec, APTIMA, or both tests. Eighteen patients had N. gonorrhoeae detected by both assays. Two had positive results by the APTIMA test but negative results by the ProbeTec test, and both patients had positive confirmatory results by the AGC assay. Eight patients had positive results by the ProbeTec assay but negative results by the APTIMA assay. N. gonorrhoeae was detected in a rectal sample from 1 individual. The remaining 7 individuals had unconfirmed results and were not included in this study [5]. Therefore, 21 patients with confirmed pharyngeal N. gonorrhoeae infection from this 2007 cohort were included in this study. Seven individuals from the cohort had positive results for pharyngeal C. trachomatis, and all were included in this study. Four had positive results for C. trachomatis by both ProbeTec and APTIMA assays. The remaining 3 had positive results by the APTIMA test but negative results by the ProbeTec test; the detection of C. trachomatis was confirmed by the ACT assay. Culture failed to detect any cases of pharyngeal N. gonorrhoeae and C. trachomatis infection in this cohort. Statistical analysis. SAS statistical software, version 9.1 (SAS Institute), was used for statistical analysis. To assess the impact of the molecular techniques introduced in 2007, Poisson regression was used to investigate the relationship between the incidence of pharyngeal N. gonorrhoeae and C. trachomatis infection (measured as the number of cases per 1000 sexually transmitted disease program visits per month) and diagnosis in Initial models included the following variables: detection in 2007 (as a step function), a within-year oscillation term (modeled by incorporating sine and cosine terms into the model with use of a fast Fourier transform) [6], and a yearly term that described linear trends over time. However, visual inspection of trend data and evaluation of model goodness of fit and Akaike s information criterion indicated that a longterm oscillation term with a 5-year period provided better fit. This term was added, giving rise to a second set of models. Because of the colinearity between the linear yearly terms and the long-term oscillation terms, the former was removed in the second set of models. Typing of pharyngeal N. gonorrhoeae isolates. For individuals with pharyngeal N. gonorrhoeae infection and positive test-of-cure results, the original and the test-of-cure isolates 1238 CID 2009:48 (1 May) Ota et al.
3 were compared using antibiotic susceptibility testing results and, where possible, the N. gonorrhoeae multiantigen sequence typing (NG-MAST) procedure [7]. The Public Health Laboratory reported antibiotic susceptibility results for penicillin, ciprofloxacin, tetracycline, cefixime, ceftriaxone, spectinomycin, and erythromycin. The susceptibility results for a given antibiotic were considered to be not different if both isolates were reported susceptible or if the reported MICs were within 1 doubling dilution of the other. The NG-MAST sequencing procedure involved sequencing highly polymorphic internal fragments within the por gene, which encodes an outer membrane protein, and the tbpb gene, which encodes the b-subunit of transferrin binding protein B [7]. The forward and reverse primers used to amplify the DNA fragments within the tbpb gene were 5 -CGTTGTCGGCAGCG- CGAAAAC-3 and 5 -TTCATCGGTGCGCTCGCCTTG-3,respectively. The forward and reverse primers for the por gene were 5 -CAATGAAAAAATCCCTGATTG-3 and 5 -TTTGCA- GATTAGAATTTGTGG-3, respectively [7]. After editing and trimming, the sequences were submitted to the NG-MAST database, where they were compared against all existing alleles and assigned a sequence type [7]. RESULTS Incidence. In total, 178 cases of pharyngeal N. gonorrhoeae and 97 cases of pharyngeal C. trachomatis infection were identified. Figure 1 illustrates the number of pharyngeal N. gonorrhoeae and C. trachomatis infections diagnosed per 1000 sexually transmitted disease program visits from 1995 through The mean incidence of pharyngeal N. gonorrhoeae was 1.62 cases per 1000 sexually transmitted disease visits per year. The mean incidence of pharyngeal C. trachomatis was 0.81 cases per 1000 sexually transmitted disease visits per year. Initial Poisson regression models demonstrated significant within-year oscillation of both pharyngeal N. gonorrhoeae ( P p.001) and C. trachomatis ( P p.002) incidence. A significant linear yearly increase in the incidence of pharyngeal C. trachomatis (incidence rate ratio [IRR], 1.20; 95% CI, ; P!.001) but not N. gonorrhoeae (IRR, 1.02; 95% CI, ; P p.34) was observed. After controlling for within-year oscillation and linear trends, a significant increase was seen in incidence of pharyngeal N. gonorrhoeae in 2007 (IRR, 1.64; 95% CI, ; P p.01). This was not the case for pharyngeal C. trachomatis (IRR, 0.77; 95% CI, ; P p.36). We created a second pair of models that replaced the linear terms with long-term oscillation (with 5-year periodicity). Significant within-year oscillation was observed for both N. gonorrhoeae ( P p.001) and C. trachomatis ( P p.002). Pharyngeal C. trachomatis demonstrated significant long-term oscillation ( P p.016). N. gonorrhoeae also exhibited a long-term oscillatory trend ( P p.06). After controlling for oscillation on both short- and long-term time scales, a significant increase in incidence in 2007 was again seen for pharyngeal N. gonorrhoeae (IRR, 1.88; 95% CI, ; P p.005) but not for C. trachomatis (IRR, 1.50; 95% CI, ; P p.31). Model Akaike s information criterion was lower for the second set of models. Urethral and rectal N. gonorrhoeae and C. trachomatis infections in patients with pharyngeal N. gonorrhoeae and C. trachomatis infections. Seventy (39.8%) of the 176 individuals with pharyngeal N. gonorrhoeae who underwent urethral testing also had N. gonorrhoeae in the urethra or urine, whereas 35 (39.3%) of the 89 who underwent rectal testing had positive results for N. gonorrhoeae in the rectum (table 1). Twelve individuals tested positive for N. gonorrhoeae at all 3 sites. Among patients with pharyngeal N. gonorrhoeae infection, 13.6% had concomitant C. trachomatis infection at another site. Fourteen (15.7%) of 89 individuals with pharyngeal C. trachomatis who were tested had positive results for C. trachomatis in urethra or urine, whereas 9 (21.4%) of 42 tested had positive results for C. trachomatis in the rectum. One individual was positive for C. trachomatis at all 3 sites. Among patients with pharyngeal C. trachomatis detected, 13.5% had concomitant N. gonorrhoeae infection at another site. There were 2 cases of Figure 1. Pharyngeal Neisseria gonorrhoeae (black bars) and Chlamydia trachomatis (gray bars) incidence by year, Hassle Free Men s Clinic, Toronto, Ontario, Canada. STD, sexually transmitted disease. Pharyngeal Gonorrhea and Chlamydia CID 2009:48 (1 May) 1239
4 Table 1. Neisseria gonorrhoeae and Chlamydia trachomatis infections at sites other than the pharynx in patients with pharyngeal N. gonorrhoeae and C. trachomatis infection. Variable No. (%) of patients Pharyngeal N. gonorrhoeae (n p 178) Pharyngeal C. trachomatis (n p 97) Urethral test Total 176 (98.9) 89 (91.8) N. gonorrhoeae detected 70 (39.8) 5 (5.6) C. trachomatis detected 15 (8.5) 14 (15.7) Both detected 8 (4.5) 2 (2.2) Rectal test Total 89 (50.0) 42 (43.3) N. gonorrhoeae detected 35 (39.3) 7 (16.7) C. trachomatis detected 9 (10.1) 9 (21.4) Both detected 5 (5.6) 3 (7.1) Received antibiotic treatment Total 177 (99.4) 88 (90.7) Cefixime 169 (95.5) Ofloxacin 8 (4.5) Azithromycin 46 (52.3) Doxycycline 42 (47.7) concomitant N. gonorrhoeae and C. trachomatis infection of the pharynx. Treatment and outcome. Overall, 99.4% of patients with pharyngeal N. gonorrhoeae infection and 90.7% of patients with pharyngeal C. trachomatis infection received treatment. Most (95.5%) of the treated pharyngeal N. gonorrhoeae patients received single-dose oral cefixime. Treatment of pharyngeal C. trachomatis was split evenly between single-dose oral azithromycin, (1 g; 52.3%) and oral doxycycline (100 mg twice daily for 7 days; 47.7%). In all 9 individuals with pharyngeal C. trachomatis and the single individual with pharyngeal N. gonorrhoeae who did not receive antibiotic therapy, medical record review showed public health documentation of 3 attempts to contact the individual to schedule a return visit for antibiotic therapy. Table 2 summarizes the individuals who had at least 1 positive test-of-cure result. Among the 122 individuals with pharyngeal N. gonorrhoeae infection who underwent test of cure, 11 (9.0%) had at least 1 positive result (patients 1 11; table 2). Ten of these individuals were treated initially with 400 mg of oral cefixime, and the remaining patient received 400 mg of oral ofloxacin. All N. gonorrhoeae culture isolates were susceptible to cefixime. The lone patient who was treated with ofloxacin was infected with a quinolone-susceptible strain. Nine of the 11 patients returned for a second course of treatment (5 with cefixime, 4 with ofloxacin) and returned subsequently for a second test of cure, in which 8 had negative results. The ninth individual (patient 10) had positive results on the second test of cure but negative results on a third test. He was originally treated with 400 mg of cefixime and received the same regimen after each positive test-of-cure result. Antibiotic susceptibility profiles of the original and test-ofcure isolates were examined for patients with N. gonorrhoeae infection (patients 1 9 and 11; patient 10 tested positive by nucleic acid amplification test only). On the basis of the susceptibility status of 4 antibiotics (penicillin, ciprofloxacin, tetracycline, and erythromycin), 8 of the 10 isolate pairs had antibiotic susceptibility profiles that were not different according to the predefined criteria. All 20 isolates were susceptible to cefixime, ceftriaxone, and spectinomycin. Original and test-of-cure isolates were available for patients 2 and 9. The NG-MAST results assigned sequence type 225 to both patient 2 isolates and sequence type 2493 to both patient 9 isolates. The antibiotic susceptibility profiles were not different for each pair. Of the 70 patients with pharyngeal C. trachomatis with testof-cure results available, 3 (4.3%) had positive results (patients 12 14). Patients 12 and 13 were initially treated with azithromycin. Both received a 7-day regimen of doxycycline after the positive test-of-cure result, and subsequent test-of-cure results were negative in both cases. Patient 14, initially treated with doxycycline, had 2 successive tests of cure that produced positive results and was retreated with the doxycycline regimen each time. A third test of cure produced negative results. Review of the medical records showed public health documentation that 13 of these 14 patients were abstaining from sexual activity at the time of the first test of cure. The 2 individuals who repeatedly had positive test-of-cure results (patients 10 and 14) were both enrolled as participants in the 2007 study. Both individuals initially had positive results by both ProbeTec and APTIMA but had negative results by culture. Both individuals also had positive results for both tests on the first test of cure (3 weeks after treatment) and the second test of cure (4 weeks after treatment). Culture and molecular assays both yielded negative results for both individuals on the third test of cure. DISCUSSION N. gonorrhoeae and C. trachomatis were regularly isolated from pharyngeal specimens at the Hassle Free Men s Clinic during the 13-year period examined. The incidence of both pharyngeal N. gonorrhoeae and C. trachomatis detection oscillated over time, a phenomenon that has not been described elsewhere. The spike in incidence of pharyngeal N. gonorrhoeae infection in 2007 was likely related to superior detection provided by the molecular testing that was introduced through the clinic s participation in a research study, which would be consistent with data emerging in other reports [5, 8]. Because only a small proportion of patients were enrolled in the study ( n p 248) 1240 CID 2009:48 (1 May) Ota et al.
5 Table 2. Patients with Neisseria gonorrhoeae and Chlamydia trachomatis infection with positive test-of-cure (TOC) results. Patient Pathogen Antibiotic therapy TOC 1 TOC 2 Different susceptibility on TOC Concurrent N. gonorrhoeae or C. trachomatis 1 N. gonorrhoeae Cefixime, 400 mg a + ND No Urethral C. trachomatis 2 b N. gonorrhoeae Cefixime, 400 mg a + No No 3 N. gonorrhoeae Cefixime, 400 mg a + Yes No 4 N. gonorrhoeae Ofloxacin, 400 mg a + No Rectal N. gonorrhoeae and C. trachomatis 5 N. gonorrhoeae Cefixime, 400 mg a + ND Yes No 6 N. gonorrhoeae Cefixime, 800 mg + No No 7 N. gonorrhoeae Cefixime, 800 mg + No Urethral C. trachomatis 8 N. gonorrhoeae Cefixime, 800 mg + No No 9 b N. gonorrhoeae Cefixime, 400 mg + No Rectal N. gonorrhoeae 10 N. gonorrhoeae Cefixime, 400 mg a + + NAAT only Rectal N. gonorrhoeae, urethral N. gonorrhoeae 11 N. gonorrhoeae Cefixime, 400 mg a + No No 12 C. trachomatis Azithromycin, 1 g + No 13 C. trachomatis Azithromycin, 1 g + No 14 C. trachomatis Doxycycline, 100 mg twice daily for7days + + NAAT only Rectal N. gonorrhoeae, urethral N. gonorrhoeae, rectal C. trachomatis NOTE., negative; +, positive; NAAT, nucleic acid amplification test; ND, second course of treatment and second TOC not performed. a Azithromycin (1 g) given empirically. b Typed with N. gonorrhoeae multiantigen sequence typing. [5], it is likely that larger-scale use of molecular testing would have increased the 2007 incidence even more. A similar spike in 2007 was not observed for pharyngeal C. trachomatis infection. This was likely because of the small number of pharyngeal C. trachomatis infections detected, regardless of the detection method used. A slight increase in incidence in 2007 may have been indistinguishable from the background oscillation described. Finally, it is unclear whether the linear increase in incidence of pharyngeal C. trachomatis infection was related to changes in sexual practices or overall incidence of C. trachomatis infections over time. It is unlikely to be related to changes in sampling, because no changes occurred in the screening practices at the study clinic during the period examined. Historically, the relevance of C. trachomatis isolated from the pharynx has been questioned [9, 10], although there is some evidence in the literature associating pharyngeal C. trachomatis with receptive oral sex [11, 12]. This pathogen is notoriously difficult to culture, especially in anatomical sites (such as the pharynx) where the microbial inoculum is presumed to be low. However, despite this, we note that 97 patients with pharyngeal C. trachomatis infection were detected during the 13-year period studied (90 by culture and 7 by molecular testing). We believe that this is significant and that it supports the practice of testing for pharyngeal C. trachomatis in high-risk populations. Although the Public Health Agency of Canada and the Centers for Disease Control and Prevention do not make specific recommendations for the treatment of individuals with pharyngeal C. trachomatis infection, they recommend that individuals with pharyngeal N. gonorrhoeae infection receive treatment for C. trachomatis if the presence of the latter has not been excluded [13, 14]. Specific screening and treatment recommendations for pharyngeal C. trachomatis infection would help to resolve this inconsistency. The necessity of performing pharyngeal testing has been questioned with the argument that individuals with pharyngeal infections will likely have a concomitant infection detected by routine urethral or urine testing. This study confirms results of other reports indicating that this is not the case [2, 5, 15]. In this cohort, relying on routine urethral and urine specimens would have missed 60.2% of pharyngeal N. gonorrhoeae infections and 84.3% of pharyngeal C. trachomatis infections, indicating that urine and urethral specimens cannot be relied on to incidentally detect pharyngeal infections. Nine percent of patients with pharyngeal N. gonorrhoeae infection who underwent tests of cure had positive results. This number is higher than that reported by McMillan and Young [16] (1 [2.2%] of 45 cases) but similar to that reported by Sathia et al. [17] (6 [10.3%] of 58 cases). Among C. trachomatis patients who underwent tests of cure, 4.3% had positive results. This small number of patients makes interpretation difficult. Mikamo et al. [18] reported that 2 (3.8%) of 52 patients with pharyngeal C. trachomatis infection had positive test-of-cure results at 15 days and 0 had positive results at 22 days after treatment with clarithromycin (400 mg/day, for 7 or 14 days). The antibiotic susceptibility profile of the original and testof-cure isolates for the pharyngeal N. gonorrhoeae patients were Pharyngeal Gonorrhea and Chlamydia CID 2009:48 (1 May) 1241
6 not different in 8 of the 10 individuals who had positive testof-cure results by culture. Although the ability of antibiotic susceptibility testing to discriminate between N. gonorrhoeae strains is limited, the lack of differences in the antibiotic susceptibility results supports treatment failure as a possible explanation for the positive test-of-cure results. In the 2 individuals whose isolates were tested with molecular typing, the NG-MAST results were identical in both cases. Public health personnel had documented that both individuals were abstaining from sexual activities at the time of the positive test-ofcure results, further supporting the explanation of treatment failure and diminishing the possibility of reinfection with the same strain from an infected partner. It has been suggested that treatment failure in such cases may be related to poor drug penetration into pharyngeal tissue [19]. Both individuals who had positive test-of-cure results detected by molecular testing had positive results on 2 successive tests of cure (patients 10 and 14). The test-of-cure results were positive by molecular testing only. In both individuals, the first test of cure was performed 3 weeks after completion of antibiotic therapy, which is consistent with current guidelines for the use of molecular testing for test of cure in the context of urethral and cervical N. gonorrhoeae infections [14]. However, the possibility that these results were related to detection of the nucleic acid of dead organisms needs to be entertained [5, 20] This study has some limitations. Completeness and accuracy are frequently a concern in retrospective studies that involve health records. The Hassle Free Men s Clinic, however, maintains written policies regarding screening, treatment, and follow-up. As a result, medical record documentation and patient treatment were remarkably systematic and complete. Also, although the NG-MAST typing system provides excellent discrimination among N. gonorrhoeae strains, culture isolates were available for only 2 of the 11 individuals with positive pharyngeal N. gonorrhoeae test-of-cure results, leaving an incomplete picture. This study demonstrated that N. gonorrhoeae and C. trachomatis are regularly detected in pharyngeal specimens of men who have sex with men and that infections will remain undetected as a consequence of the poor sensitivity of culture and failure to obtain appropriate specimens from this site. There was a significant failure rate for both pharyngeal N. gonorrhoeae and C. trachomatis infections that were treated with standard antibiotic regimens originally developed for treatment of male urethral and female cervical infections. These failure rates were higher than those associated with treatment of urethral and cervical infections (3% for 1 g of azithromycin and 2% for the 7-day regimen of doxycycline (100 mg twice daily), for treatment of C. trachomatis; 2% 3% for 400 mg of cefixime for treatment of N. gonorrhoeae) [21 23]. These data suggest that specific antibiotic treatment regimens for pharyngeal N. gonorrhoeae and C. trachomatis need to be developed and formally evaluated. Acknowledgments We thank Allan Lau and Irene Martin at the National Microbiology Laboratory and Lynn Towns, Gary Brienza, and Dr. Frances Jamieson at the Public Health Laboratory, Ontario Agency for Health Protection and Promotion, for their assistance with the molecular typing in this study. We also thank Leo Mitterni and Elmer Bagares from the Hassle Free Men s Clinic for their assistance with data collection. Potential conflicts of interest. All authors: no conflicts. References 1. Centers for Disease Control and Prevention. Increases in unsafe sex and rectal gonorrhea among men who have sex with men San Francisco, MMWR Morb Mortal Wkly Rep 1999; 48: Kent CK, Chaw JK, Wong W, et al. Prevalence of rectal, urethral, and pharyngeal chlamydia and gonorrhea detected in 2 clinical settings among men who have sex with men: San Francisco, California, Clin Infect Dis 2005; 41: Lafferty WE, Hughes JP, Handsfield HH. Sexually transmitted diseases in men who have sex with men: acquisition of gonorrhea and nongonococcal urethritis by fellatio and implications for STD/HIV prevention. Sex Transm Dis 1997; 24: Morris SR, Klausner JD, Buchbinder SP, et al. Prevalence and incidence of pharyngeal gonorrhea in a longitudinal sample of men who have sex with men: the EXPLORE study. Clin Infect Dis 2006; 43: Ota K, Tamari I, Smieja M, et al. Detection of Neisseria gonorrhoeae and Chlamydia trachomatis in pharyngeal and rectal specimens using the BD ProbeTec ET system, the Gen-Probe APTIMA Combo 2 assay and culture. Sex Transm Infect 2009 (Epub ahead of print). 6. Diggle P. Spectral Analysis. In: Time series, a biostatistical introduction. Oxford, England: Oxford University Press, 1989: NG-MAST. Neisseria gonorrhoeae multi antigen sequence typing. Available at: Accessed 2 October Schachter J, Moncada J, Liska S, Shayevich C, Klausner JD. Nucleic acid amplification tests in the diagnosis of chlamydial and gonococcal infections of the oropharynx and rectum in men who have sex with men. Sex Transm Dis 2008; 35: Jebakumar SPR, Storey C, Lusher M, Nelson J, Goorney B, Haye KR. Value of screening for oro-pharyngeal Chlamydia trachomatis infection. J Clin Pathol 1995; 48: Coughlan E, Young S. Screening for pharyngeal Chlamydia trachomatis in asymptomatic men who have sex with men. N Z Med J 2006; 119: U McMillan A, Sommerville RG, McKie PMK. Chlamydia infection in homosexual men: frequency of isolation of Chlamydia trachomatis from the urethra, ano-rectum, and pharynx. Br J Vener Dis 1981; 57: Jones RB, Rabinovitch RA, Katz BP, et al. Chlamydia trachomatis in the pharynx and rectum of heterosexual patients at risk for genital infection. Ann Intern Med 1985; 102: Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, MMWR Morb Mortal Wkly Rep 2006; 55: Public Health Agency of Canada. Canadian Guidelines on Sexually Transmitted Infections, 2006 edition. Ottawa, Canada: Public Health Agency of Canada, Page-Shafer K, Graves A, Kent C, et al. Increased sensitivity of DNA amplification testing for the detection of pharyngeal gonorrhea in men who have sex with men. Clin Infect Dis 2002; 34: McMillan A, Young H. The treatment of pharyngeal gonorrhoea with a single oral dose of cefixime. Int J STD AIDS 2007; 18: Sathia L, Ellis B, Phillip S, Winston A, Smith A. Pharyngeal gonor CID 2009:48 (1 May) Ota et al.
7 rhoea is dual therapy the way forward? Int J STD AIDS 2007;18: Mikamo H. Ninomiya M. Tamaya T. Clinical efficacy of clarithromycin against uterine cervical and pharyngeal Chlamydia trachomatis and the sensitivity of polymerase chain reaction to detect C. trachomatis at various time points after treatment. J Infect Chemother 2003; 9: Manavi K, Young H, McMillan A. The outcome of oropharyngeal gonorrhoea treatment with different regimens. Int J STD AIDS 2005; 16: Vogels WH, van Voorst Vader PC, Schröder FP. Chlamydia trachomatis infection in a high-risk population: comparison of polymerase chain reaction and cell culture for diagnosis and follow-up. J Clin Microbiol 1993; 31: Hansfield HH, McCormack WM, Hook EW 3rd, et al.; The Gonorrhoea Treatment Study Group. A comparison of single-dose cefixime with ceftriaxone as treatment for uncomplicated gonorrhoea. N Engl JMed1991; 325: Portilla I, Lutz B, Montalvo M, Mogabgab WJ. Oral cefixime versus intramuscular ceftriaxone in patients with uncomplicated gonococcal infections. Sex Transm Dis 1992; 19: Lau CY, Qureshi AK. Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials. Sex Transm Dis 2002; 29: Pharyngeal Gonorrhea and Chlamydia CID 2009:48 (1 May) 1243
Azithromycin for Rectal Chlamydia: Is it Time to Leave Azithromycin on the Shelf?...Not Yet. Jordan, Stephen J. MD, PhD; Geisler, William M.
Azithromycin for Rectal Chlamydia: Is it Time to Leave Azithromycin on the Shelf?...Not Yet Jordan, Stephen J. MD, PhD; Geisler, William M. MD, MPH From the Department of Medicine, University of Alabama
More informationTransmission from the Oropharynx to the Urethra among Men who have Sex with Men
MAJOR ARTICLE Chlamydia trachomatis and Neisseria gonorrhoeae Transmission from the Oropharynx to the Urethra among Men who have Sex with Men Kyle T. Bernstein, 1 Sally C. Stephens, 1 Pennan M. Barry,
More informationOriginal Study. Culture of Non-Genital Sites Increases the Detection of Gonorrhea in Women
J Pediatr Adolesc Gynecol (2010) 23:246e252 Original Study Culture of Non-Genital Sites Increases the Detection of Gonorrhea in Women Courtney M. Giannini 1, Hye K. Kim, BS 1, Jonathan Mortensen 3, Joel
More informationManagement of Gonorrhea in Adolescents and Adults in the United States
SUPPLEMENT ARTICLE Management of Gonorrhea in Adolescents and Adults in the United States Sarah Kidd 1 and Kimberly A. Workowski 1,2 1 Division of STD Prevention, Centers for Disease Control and Prevention,
More information6/11/15. BACTERIAL STDs IN A POST- HIV WORLD. Learning Objectives. How big a problem are STIs in the U.S.?
BACTERIAL STDs IN A POST- HIV WORLD Tracey Graney, PhD, MT(ASCP) Monroe Community College Learning Objectives Describe the epidemiology and incidence of bacterial STDs in the U.S. Describe current detection
More informationGenital Chlamydia and Gonorrhea Epidemiology, Diagnosis, and Management. William M. Geisler M.D., M.P.H. University of Alabama at Birmingham
Genital Chlamydia and Gonorrhea Epidemiology, Diagnosis, and Management William M. Geisler M.D., M.P.H. University of Alabama at Birmingham Chlamydia and Gonorrhea Current Epidemiology Chlamydia Epidemiology
More informationEvaluation of CDC-Recommended Approaches for Confirmatory Testing of Positive Neisseria gonorrhoeae Nucleic Acid Amplification Test Results
JOURNAL OF CLINICAL MICROBIOLOGY, May 2008, p. 1614 1619 Vol. 46, No. 5 0095-1137/08/$08.00 0 doi:10.1128/jcm.02301-07 Copyright 2008, American Society for Microbiology. All Rights Reserved. Evaluation
More informationThe objectives of this presentation are; to increase awareness of the issue of antimicrobial resistant gonorrhea, and to inform primary care and
1 Antimicrobial resistant gonorrhea is an emerging public health threat that needs to be addressed. Neisseria gonorrhoeae is able to develop resistance to antimicrobials quickly. Effective antibiotic stewardship
More informationExtragenital Chlamydia and Gonorrhea. Angel Stachnik, MPH Sr. Epidemiologist Office of Epidemiology and Disease Surveillance
Extragenital Chlamydia and Gonorrhea Angel Stachnik, MPH Sr. Epidemiologist Office of Epidemiology and Disease Surveillance Rate of Chlamydia (CT) and Gonorrhea (GC), Clark County, 2012-2016 600 Rate per
More informationUPDATE MOLECULAR DIAGNOSTICS IN SEXUAL HEALTH. Dr Arlo Upton Clinical Microbiologist Labtests Auckland
UPDATE MOLECULAR DIAGNOSTICS IN SEXUAL HEALTH Dr Arlo Upton Clinical Microbiologist Labtests Auckland Talk outline Chlamydia trachomatis NAAT What does a positive test mean Interpreting low level positives
More informationThis article was published in an Elsevier journal. The attached copy is furnished to the author for non-commercial research and education use, including for instruction at the author s institution, sharing
More informationServices for GLBTQ Youth
Sexual Health Care Services for GLBTQ Youth Gale R Burstein, MD, MPH, FAAP, FSAHM Erie County Commissioner of Health Buffalo, NY Agenda Introduction Epidemiology Sexual health care services for YMSM Sexual
More informationDuration of Persistence of Gonococcal DNA Detected by Ligase Chain Reaction in Men and Women following Recommended Therapy for Uncomplicated Gonorrhea
JOURNAL OF CLINICAL MICROBIOLOGY, Oct. 2002, p. 3596 3601 Vol. 40, No. 10 0095-1137/02/$04.00 0 DOI: 10.1128/JCM.40.10.3596 3601.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.
More informationTreatment resistant STIs relevant to MSM
Treatment resistant STIs relevant to MSM David A. Lewis FRCP (UK) PhD Centre for HIV and STIs National Institute for Communicable Diseases (NHLS) Johannesburg, South Africa Regional Director, IUSTI Africa
More informationAnswers to those burning questions -
Answers to those burning questions - Ann Avery MD Infectious Diseases Physician-MetroHealth Medical Center Assistant Professor- Case Western Reserve University SOM Medical Director -Cleveland Department
More informationRETURN OF THE CLAP: Emerging Issues in Gonorrhea Management and Antibiotic Resistance
RETURN OF THE CLAP: Emerging Issues in Gonorrhea Management and Antibiotic Resistance Ina Park, MD, MS University of California San Francisco California Prevention Training Center DISCLOSURE No Relevant
More informationDETECTION OF NEISSERIA GONORRHOEAE USING MOLECULAR METHODS
NATIONAL STANDARD METHOD DETECTION OF NEISSERIA GONORRHOEAE USING MOLECULAR METHODS QSOP 62 Issued by Standards Unit, Department for Evaluations,Standards and Training Centre for Infections Issue no: 1
More informationScottish Bacterial Sexually Transmitted Infections Reference Laboratory (SBSTIRL) User Manual Jan 2018
Scottish Bacterial Sexually Transmitted Infections Reference Laboratory (SBSTIRL) User Manual Jan 2018 Page 1 Contents 1 Introduction Page 3 2 Contact details Page 4 3 Opening hours Page 4 4 Services provided
More informationClinical Guidelines Update (aka Know Your NAATs)
Clinical Guidelines Update (aka Know Your NAATs) WARNING: contains adult themes, sexual references and pictures that may be disturbing! Dr Heather Young Christchurch Sexual Health Centre heather.young@cdhb.health.nz
More informationEmergence et impact clinique de la résistance aux antibiotiques chez Chlamydia trachomatis, Neisseria gonorrhoeae, les mycoplasmes
Emergence et impact clinique de la résistance aux antibiotiques chez Chlamydia trachomatis, Neisseria gonorrhoeae, les mycoplasmes Cécile Bébéar French National Center for bacterial STIs Bordeaux University
More informationDr Selena Singh. Guy s and St Thomas NHS Foundation Trust, London THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014
THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Dr Selena Singh Guy s and St Thomas NHS Foundation Trust, London 1-4 April 2014, Arena and Convention Centre Liverpool Performance of ceftriaxone 500mgcontaining
More information5/1/2017. Sexually Transmitted Diseases Burning Questions
Sexually Transmitted Diseases Burning Questions Jeffrey D. Klausner, MD, MPH Professor of Medicine and Public Health University of California Los Angeles Los Angeles, California FORMATTED: 04-03-17 Financial
More informationREPORT ON THE ENHANCED SURVEILLANCE OF ANTIMICROBIAL-RESISTANT GONORRHEA
i Report on the enhanced surveillance of antimicrobial-resistant gonorrhea REPORT ON THE ENHANCED SURVEILLANCE OF ANTIMICROBIAL-RESISTANT GONORRHEA RESULTS FROM THE 2014 PILOT i TO PROMOTE AND PROTECT
More informationGuidelines for the Laboratory Detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Treponema pallidum Testing
Guidelines for the Laboratory Detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Treponema pallidum Testing Recommendations from the an expert consultation meeting held at CDC January 13-15,
More informationNucleic Acid Amplification Tests for Diagnosis of Neisseria gonorrhoeae and Chlamydia trachomatis Rectal Infections
JOURNAL OF CLINICAL MICROBIOLOGY, May 2010, p. 1827 1832 Vol. 48, No. 5 0095-1137/10/$12.00 doi:10.1128/jcm.02398-09 Copyright 2010, American Society for Microbiology. All Rights Reserved. Nucleic Acid
More informationClinical Practice Objectives
STD Essentials for the Busy Clinician Susan S. Philip, MD, MPH Assistant Professor, Division of Infectious Diseases, UCSF Director, STD Prevention and Control Services San Francisco Department of Public
More informationIn vitro assessment of dual drug combinations to inhibit growth of Neisseria gonorrhoeae
AAC Accepted Manuscript Posted Online 26 January 2015 Antimicrob. Agents Chemother. doi:10.1128/aac.04127-14 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 2 In vitro assessment
More informationendocervical, urethral, rectal, and pharyngeal
Genitourin Med 1997;73:493-497 Original article Department of Infectious Diseases, Aarhus University Hospital, PP rumsgade 11, DK- 8 Aarhus C, L stergaard Department of Dermato-Venerology, University of
More informationSTD Essentials for the Busy Clinician. Stephanie E. Cohen, MD, MPH
STD Essentials for the Busy Clinician Stephanie E. Cohen, MD, MPH Assistant Professor, Division of Infectious Diseases, UCSF Medical Director, City Clinic San Francisco Department of Public Health Disclosures
More informationNeisseria gonorrhoeae: The Ontario perspective. Michael Whelan and Dr. Vanessa Allen PHO Grand Rounds, May 5, 2015
Neisseria gonorrhoeae: The Ontario perspective Michael Whelan and Dr. Vanessa Allen PHO Grand Rounds, May 5, 2015 Objectives Participants will be able to: Describe preferred specimen collection for testing
More informationNothing to disclose.
Update on Diagnosis and Treatment Lisa Winston, MD University of California, San Francisco/ Zuckerberg San Francisco General Nothing to disclose. 1 This talk will be a little depressing Rising incidence
More information6. Gonococcal antimicrobial susceptibility
6. Gonococcal antimicrobial susceptibility Key points Gonococcal AMR continues to increase worldwide and could lead to a pandemic of extensively drug-resistant (XDR) N. gonorrhoeae with serious public
More informationKhalil G. Ghanem, MD, PhD Associate Professor of Medicine Johns Hopkins University School of Medicine. April 2, 2014
Khalil G. Ghanem, MD, PhD Associate Professor of Medicine Johns Hopkins University School of Medicine April 2, 2014 E-mail your questions for the presenter to: maphtc@jhsph.edu DISCLOSURES OFF- LABEL USES
More informationChlamydia Trachomatis and Neisseria Gonorrhoeae. Khalil G. Ghanem, MD Johns Hopkins University
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationSTDs in HIV Clinical Care: New Guidelines on Treatment and Prevention
STDs in HIV Clinical Care: New Guidelines on Treatment and Prevention Palliative Care Conference Faculty Development Conference August 13, 2015 Steven C. Johnson M.D. Director, University of Colorado HIV/AIDS
More informationUpdate on Sexually Transmitted Infections among Persons Living with HIV
Update on Sexually Transmitted Infections among Persons Living with HIV Stephen A. Berry, MD PhD Assistant Professor of Medicine Johns Hopkins University Division of Infectious Diseases Abbreviations and
More informationSexually Transmitted Diseases. Summary of CDC Treatment Guidelines
DC 2015 Sexually Transmitted Diseases Summary of CDC Treatment Guidelines These summary guidelines reflect the June 2015 update to the 2010 CDC Guidelines for Treatment of Sexually Transmitted Diseases.
More informationGonorrhea Antimicrobial Resistance in Alberta. Gonorrhea Antimicrobial Resistance Review
2011 Review in Alberta Alberta Gonorrhea AMR Surveillance Working Group November 2013 2011 Review Background Gonorrhea remains one of the oldest infections known to man. Infections can result in significant
More informationChlamydia trachomatis and Neisseria gonorrhoeae are the
ORIGINAL STUDY Screening of Oropharynx and Anorectum Increases Prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae Infection in Female STD Clinic Visitors Remco P. H. Peters, MD, PhD,* Noëmi
More informationScottish Bacterial Sexually Transmitted Infections Reference Laboratory (SBSTIRL) User Report for the period January - December 2011
Scottish Bacterial Sexually Transmitted Infections Reference Laboratory (SBSTIRL) User Report for the period January - ember 211 Kirstine Eastick PhD FRCPath (Director) SBSTIRL, Microbiology Edinburgh
More informationCost-effective treatment of uncomplicated gonorrhoea including co-infection with Chlamydia trachomatis Genc M, Mardh P A
Cost-effective treatment of uncomplicated gonorrhoea including co-infection with Chlamydia trachomatis Genc M, Mardh P A Record Status This is a critical abstract of an economic evaluation that meets the
More informationTrends of sexually transmitted diseases and antimicrobial resistance in Neisseria gonorrhoeae
International Journal of Antimicrobial Agents 31S (2008) S35 S39 Trends of sexually transmitted diseases and antimicrobial resistance in Neisseria gonorrhoeae T. Matsumoto Department of Urology, School
More informationSTI Indicators by STI
STI Indicators by STI Table of Contents pg. 2 Sexual History pg. 3-4 Syphilis pg. 5-6 Gonorrhea pg. 7-9 Chlamydia pg. 10 HIV/PrEP 1 Sexual History Comprehensive Sexual History Elements Percentage of patients
More informationNIH Public Access Author Manuscript Sex Transm Infect. Author manuscript; available in PMC 2013 June 04.
NIH Public Access Author Manuscript Published in final edited form as: Sex Transm Infect. 2013 June ; 89(4): 305 307. doi:10.1136/sextrans-2012-050686. Comparison of self-obtained penile-meatal swabs to
More informationOne week of doxycycline is an effective treatment for asymptomatic rectal Chlamydia trachomatis infection
One week of doxycycline is an effective treatment for asymptomatic rectal Chlamydia trachomatis infection A Elgalib, A Skingsley, O Dosekun, S Alexander, CYW Tong, JA White. Ali Elgalib Consultant in GUM/HIV
More informationTherapy for Uncomplicated Gonorrhea in Women
Infectious Diseases in Obstetrics and Gynecology 5:370-375 (1997) (C) 1998 Wiley-Liss, Inc. Grepafloxacin Versus Cefixime as Single-Dose Therapy for Uncomplicated Gonorrhea in Women T.F. Mroczkowski,*
More informationCDC Grand Rounds: The Growing Threat of Multidrug-
Page 1 of 8 Morbidity and Mortality Weekly Report (MMWR) CDC Grand Rounds: The Growing Threat of Multidrug- Resistant Gonorrhea Weekly February 15, 2013 / 62(06);103-106 Although gonorrhea has afflicted
More informationFactors associated with repeat symptomatic gonorrhea infections among men who have sex with men, Bangkok, Thailand
Factors associated with repeat symptomatic gonorrhea infections among men who have sex with men, Bangkok, Thailand Pattanasin S. 1, Luechai P. 1, Sriporn A. 1, Tongtoyai J. 1, Sukwicha W. 1, Kongpechsatit
More informationProfessor Jonathan Ross
SECOND JOINT CONFERENCE OF BHIVA AND BASHH 2010 Professor Jonathan Ross Whittall Street Clinic, Birmingham COMPETING INTEREST OF FINANCIAL VALUE > 1,000: Speaker Name Statement Professor Ross has received
More informationSingle-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea
Original Article Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea Stephanie N. Taylor, M.D., Jeanne Marrazzo, M.D., M.P.H., Byron E. Batteiger, M.D., Edward W. Hook, III, M.D.,
More informationGonorrhea. Epidemiology in the United States. Epidemiology by Demographics. This is a PDF version of the following document:
National STD Curriculum PDF created November 7, 2018, 3:02 am Gonorrhea This is a PDF version of the following document: Disease Type 1: Pathogen-Based Diseases Disease 6: Gonorrhea You can always find
More informationCHARLOTTE K. KENT, MPH,* JANICE K. CHAW, MPH,* ROBERT P. KOHN, MPH,* YING Q. CHEN, PHD, AND JEFFREY D. KLAUSNER MD, MPH*
Sexually Transmitted Diseases, October 2004, Vol. 31, No. 10, p.596 600 DOI: 10.1097/01.olq.0000140011.93104.32 Copyright 2004, American Sexually Transmitted Diseases Association All rights reserved. Studies
More informationInternationell utblick STI/HIV i världen
Internationell utblick STI/HIV i världen Magnus Unemo, PhD, Assoc. Professor, Director Swedish Reference Laboratory for Pathogenic Neisseria, Department of Laboratory Medicine, Microbiology Örebro University
More informationGuidance on the use of molecular testing for Neisseria gonorrhoeae in Diagnostic Laboratories 2011
Guidance on the use of molecular testing for Neisseria gonorrhoeae in Diagnostic Laboratories 2011 Molecular testing for gonorrhoea working group (see Appendix) Prepared by Kirstine Eastick March 2012-1
More informationRecent Trends in Neisseria gonorrhoeae Infection
Sexually Transmitted Diseases Recent Trends in Neisseria gonorrhoeae Infection JMAJ 45(12): 499 505, 2002 Shoichi ONODERA Professor, Department of Urology, The Jikei University School of Medicine Abstract:
More informationBECAUSE OF NEISSERIA GONORrhoeae
PRELIMINARY COMMUNICATION Neisseria gonorrhoeae Treatment Failure and Susceptibility to Cefixime in Toronto, Canada Vanessa G. Allen, MD, MPH Leo Mitterni Christine Seah, MLT Anuradha Rebbapragada, PhD
More informationSexually Transmitted Infection surveillance in Northern Ireland An analysis of data for the calendar year 2011
Sexually Transmitted Infection surveillance in Northern Ireland 2012 An analysis of data for the calendar year 2011 Contents Page Summary points. 3 Surveillance arrangements and sources of data.. 4 1:
More informationAPTIMA Combo 2 Testing Detected Additional Cases of Neisseria. gonorrhoeae in Men and Women in Community Settings. * Corresponding Author at:
JCM Accepts, published online ahead of print on 16 March 2011 J. Clin. Microbiol. doi:10.1128/jcm.02062-10 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions. All
More informationThis genus includes two species pathogenic for humans:
THE GENUS NEISSERIA Neisseriae are gramnegative cocci arranged in pairs, so they are diplococci. This genus includes two species pathogenic for humans: N. gonorrhoeae (s.c. gonococci) N. meningitidis (s.c.
More information* these authors contributed equally to the preparation of this report
AAC Accepts, published online ahead of print on June 00 Antimicrob. Agents Chemother. doi:0./aac.000-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationEffect of Endocervical Specimen Adequacy for Detection of ACCEPTED. Wyoming Public Health Laboratory, 517 Hathaway Bldg., 2300 Capitol Ave.
JCM Accepts, published online ahead of print on October 00 J. Clin. Microbiol. doi:./jcm.001-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationThe epidemiology of Chlamydia trachomatis infection. Chlamydia trachomatis Infection in Asymptomatic Men. Background
Chlamydia trachomatis Infection in Asymptomatic Men D. Scott LaMontagne, MPH, David N. Fine, PhD, Jeanne M. Marrazzo, MD, MPH Background: Methods: Results: Conclusions: The epidemiology of Chlamydia trachomatis
More informationSTI Treatment Guidelines. Teodora Wi. Training Course in Sexual and Reproductive Health Research
Teodora Wi Geneva, 28 August 2017 STI Treatment Guidelines Teodora Wi Training Course in Sexual and Reproductive Health Research 2017 Twitter @HRPresearch 1 STI treatment guidelines Neisseria gonorrhoeae
More informationSexually transmitted diseases (STDs) at extragenital sites are
ORIGINAL STUDY Standard Symptom- and Sexual HistoryYBased Testing Misses Anorectal Chlamydia trachomatis and Neisseria gonorrhoeae Infections in Swingers and Men Who Have Sex With Men Geneviève A. F. S.
More informationDisclosures. STD Screening for Women. Chlamydia & Gonorrhea. I have no disclosures or conflicts of interest to report.
Disclosures Management of STIs: Challenges in Practice I have no disclosures or conflicts of interest to report. Alison O. Marshall, MSN, FNP-C Associate Professor of Practice & Director of the Family
More informationUse of Nucleic Acid Amplification Testing for the Diagnosis of Anorectal Sexually. Transmitted Infections. Lisa A. Cosentino 1,2.
JCM Accepts, published online ahead of print on 4 April 2012 J. Clin. Microbiol. doi:10.1128/jcm.00185-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Use of Nucleic Acid
More information2012 California Clinical Laboratory Survey: STD/HIV/Hepatitis Testing
2012 California Clinical Laboratory Survey: STD/HIV/Hepatitis Testing Joan M. Chow, MPH, DrPH Surveillance, Epidemiology, Assessment & Evaluation Section Sexually Transmitted Disease Control Branch Division
More information4/6/17 UNPRECEDENTED HIGH. Shelagh Larson, RNC, WHNP, NCMP
Shelagh Larson, RNC, WHNP, NCMP UNPRECEDENTED HIGH Total combined cases of chlamydia, gonorrhea, and syphilis reported in 2015 reached the highest number ever, according to the annualmore than 1.5 million
More informationControls for Chlamydia trachomatis and Neisseria gonorrhoea
Controls for Chlamydia trachomatis and Neisseria gonorrhoea Mark Manak, Ph.D., SeraCare Life Sciences Gaithersburg, MD USA SoGAT Clinical Diagnostic Meeting NIBSC, South Mimms, UK June 25, 2008 C. trachomatis
More informationNovos desafios para controlar as infecções sexualmente transmissíveis [New Challenges in Managing Sexually Transmitted Infections]
Novos desafios para controlar as infecções sexualmente transmissíveis [New Challenges in Managing Sexually Transmitted Infections] Khalil Ghanem, MD, PhD Associate Professor of Medicine Directors, STD/HIV/TB
More informationLearning Objectives. STI Update. Case 1 6/1/2016
Learning Objectives STI Update June 16 th, 2016 Madhu Choudhary, MD. FIDSA Assoc. Prof of Medicine Albany Medical College Review screening recommendations for STI in different patient populations Describe
More informationReceived 26 November 2008/Returned for modification 4 February 2009/Accepted 2 April 2009
JOURNAL OF CLINICAL MICROBIOLOGY, June 2009, p. 1657 1662 Vol. 47, No. 6 0095-1137/09/$08.00 0 doi:10.1128/jcm.02269-08 Copyright 2009, American Society for Microbiology. All Rights Reserved. Evaluation
More informationExtra-genital STIs: An update. Luis F. Barroso, M.D. Associate Professor Wake Forest Baptist Health
Extra-genital STIs: An update Luis F. Barroso, M.D. Associate Professor Wake Forest Baptist Health Grant Support: NIH Disclosure: Off-Label Disclosure This presentation will include discussion of the following
More informationAppendix A: Disease-Specific Chapters
Infectious Diseases Protocol Appendix A: Disease-Specific Chapters Chapter: Gonorrhoea Revised January 2014 Gonorrhoea Communicable Virulent Health Protection and Promotion Act, Section 1 (1) Health Protection
More informationReceived 16 December 2005/Returned for modification 6 February 2006/Accepted 6 May 2006
JOURNAL OF CLINICAL MICROBIOLOGY, July 2006, p. 2512 2517 Vol. 44, No. 7 0095-1137/06/$08.00 0 doi:10.1128/jcm.02620-05 Copyright 2006, American Society for Microbiology. All Rights Reserved. Detection
More informationExtragenital Gonorrhea and Chlamydia among MSM
Extragenital Gonorrhea and Chlamydia among MSM Laura Quilter, MD Infectious Disease and STD PTC Fellow University of Washington Division of Allergy and Infectious Diseases 3/28/2016 uwptc@uw.edu uwptc.org
More informationScreening & Treating Chlamydia in Primary Care. Wednesday, September 21, 2016
Screening & Treating Chlamydia in Primary Care Wednesday, September 21, 2016 We Want To Hear From You! Type questions into the Questions Pane at any time during this presentation Patient-Centered Primary
More informationTimby/Smith: Introductory Medical-Surgical Nursing, 9/e
Timby/Smith: Introductory Medical-Surgical Nursing, 9/e Chapter 62: Caring for Clients With Sexually Transmitted Diseases Slide 1 Epidemiology Introduction Study of the occurrence, distribution, and causes
More informationSexually Transmitted Infection Treatment and HIV Prevention
Sexually Transmitted Infection Treatment and HIV Prevention Toye Brewer, MD Co-Director, Fogarty International Training Program University of Miami Miller School of Medicine STI Treatment and HIV Prevention.
More informationControls for Chlamydia trachomatis and Neisseria gonorrhoea
Controls for Chlamydia trachomatis and Neisseria gonorrhoea Mark Manak, Ph.D., Phil Moen, Ph.D., Bharathi Anekella, Ph.D SeraCare Life Sciences Gaithersburg, MD USA SoGAT Clinical Diagnostic Meeting NIBSC,
More informationNew CT/GC Tests. CDC National Infertility Prevention Project Laboratory Update Region II May 13-14, 2009
CDC National Infertility Prevention Project Laboratory Update Region II May 13-14, 2009 Richard Steece, Ph.D., D(ABMM) DrRSteece@aol.com New CT/GC Tests New Nucleic Acid Amplification Tests (NAATs) for
More informationOriginal article. Office of Disease Prevention and Control, region 10 Chiang Mai, 2 Sanpatong Hospital, 3
Original article A retrospective study of relationship between white blood cell counts in cervical discharge and Chlamydial cervicitis among young adults: is the simple microscope an alternative method
More informationExtragenital Infection with Sexually Transmitted Pathogens
Infectious Diseases Extragenital Infection with Sexually Transmitted Pathogens JMAJ 46(9): 41 49, 23 Hiroyuki KOJIMA Former Chief of Urology, Japanese Red Cross Medical Center Abstract: The significant
More informationDisclosure Information Julie Stoltey, MD MPH
Courtesy CDC Public Health Image Library The New Yorker 2012 2016 Update on Testing, Treatment, and Gonorrhea Resistance Julie Stoltey, MD, MPH STD Control Branch-California Dept. of Public Health Assistant
More information2014 CDC GUIDELINES CHLAMYDIA & GONORRHEA DIAGNOSTICS. Barbara Van Der Pol, PhD, MPH University of Alabama at Birmingham
2014 CDC GUIDELINES CHLAMYDIA & GONORRHEA DIAGNOSTICS Barbara Van Der Pol, PhD, MPH University of Alabama at Birmingham DISCLOSURES Honorarium, Speaking Fees or Research Support Atlas Genetics BD Diagnostics
More informationThe Emerging Threat of Cephalosporin (& Multidrug) Resistant Gonorrhea
The Emerging Threat of Cephalosporin (& Multidrug) Resistant Gonorrhea Robert D. Kirkcaldy, MD, MPH Division of STD Prevention National Center for HIV/AIDS, Viral Hepatitis, TB and STD Prevention Centers
More informationSinan B. Issa, Dept. of Microbiology, College of Medicine, Tikrit University
A study on Mycoplasma and Ureaplasma species and their association with gonorrhea in infertile Sinan B. Issa, Dept. of Microbiology, College of Medicine, Tikrit University Abstract Humans can be infected
More informationOAML Guideline on the Investigation of Genital Tract Infections November, 2015
OAML Guideline on the Investigation of Genital Tract Infections November, 2015 1. Purpose The purpose of this guideline is to provide ordering clinicians with a clear and concise reference for the investigation
More informationSexually transmitted infections (in women)
Sexually transmitted infections (in women) Timothy Kremer, MD Assistant Professor, Department of Obstetrics and Gynecology University of North Texas Health Science Center Last official CDC guidelines:
More informationChlamydia. By Madhuri Reddy
Chlamydia By Madhuri Reddy Disease- Chlamydia Etiologic agent Chlamydial infection is caused by the genera Chlamydia, of which the type of species is Chlamydia trachomatis. This infection can causes diseases
More informationCHLAMYDIA/GC AMPLIFIED RNA ASSAY
Lab Dept: Test Name: Microbiology/Virology CHLAMYDIA/GC AMPLIFIED RNA ASSAY General Information Lab Order Codes: CGRNA Synonyms: CPT Codes: Test Includes: Chlamydia trachomatis/neisseria gonorrhoeae by
More informationSexually Transmitted Infection surveillance in Northern Ireland An analysis of data for the calendar year 2016
Sexually Transmitted Infection surveillance in Northern Ireland 2017 An analysis of data for the calendar year 2016 Contents Page Summary points. 3 Surveillance arrangements and sources of data.. 4 1:
More informationAntimicrobial resistance and molecular epidemiology of Neisseria gonorrhoeae in New Zealand,
Antimicrobial resistance and molecular epidemiology of Neisseria gonorrhoeae in New Zealand, 2014-15 December 2015 PREPARED FOR: CLIENT REPORT No: PREPARED BY: Ministry of Health FW15061 Helen Heffernan,
More informationProfessor Jonathan Ross. Dr Melinda Tenant-Flowers. University Hospitals Birmingham NHS Trust. King s College Hospital NHS Foundation Trust, London
THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Professor Jonathan Ross University Hospitals Birmingham NHS Trust Dr Melinda Tenant-Flowers King s College Hospital NHS Foundation Trust, London 1-4 April
More informationPatient-Delivered Partner Treatment for Male Urethritis: A Randomized, Controlled Trial
MAJOR ARTICLE Patient-Delivered Partner Treatment for Male Urethritis: A Randomized, Controlled Trial Patricia Kissinger, 1 Hamish Mohammed, 1 Gwangi Richardson-Alston, 1 Jami S. Leichliter, 3 Stephanie
More informationCDC Laboratory Update
CDC Laboratory Update Chlamydia and Gonorrhea Laboratory Guidelines Overview of the APHL / CDC STD Steering Committee Laboratory Recommendations for the Detection of Chlamydia trachomatis, Neisseria gonorrhoeae
More informationSexually transmitted infections (in women)
Sexually transmitted infections (in women) Timothy Kremer, MD Assistant Professor, Department of Obstetrics and Gynecology University of North Texas Health Science Center Last official CDC guidelines:
More informationRésistance bactérienne au cours des Infections Sexuellement Transmissibles Cécile Bébéar
Résistance bactérienne au cours des Infections Sexuellement Transmissibles Cécile Bébéar French Na*onal Center for bacterial STIs Bordeaux University hospital, Bordeaux, France University of Bordeaux,
More informationCASE-BASED SMALL GROUP DISCUSSION MHD II SESSION VI. Friday, MARCH 20, 2015 STUDENT COPY
MHD II, Session VI, STUDENT Copy Page 1 CASE-BASED SMALL GROUP DISCUSSION MHD II SESSION VI Friday, MARCH 20, 2015 STUDENT COPY Resource for cases: ACP Medicine (Scientific American Medicine) - Vaginitis
More informationRate and Predictors of Repeat Chlamydia trachomatis Infection Among Men
Sexually Transmitted Diseases, December 2008, Vol. 35, 12, p.000 000 DOI: 10.1097/OLQ.0b013e31817247b2 Copyright 2008, American Sexually Transmitted Diseases Association All rights reserved. Rate and Predictors
More information